In Vivo Activity of Darobactin D22 Against Gram-Negative Pathogens
Author Information
Author(s): Kany Andreas M., Fries Franziska, Seyfert Carsten E., Porten Christoph, Deckarm Selina, Chacón Ortiz María, Dubarry Nelly, Vaddi Swapna, Große Miriam, Bernecker Steffen, Sandargo Birthe, Müller Alison V., Bacqué Eric, Stadler Marc, Herrmann Jennifer, Müller Rolf
Primary Institution: Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)
Hypothesis
Can the biosynthetic darobactin analogue D22 effectively combat infections caused by critical Gram-negative pathogens in vivo?
Conclusion
Darobactin D22 shows significant antibacterial activity against key Gram-negative pathogens in various in vivo models.
Supporting Evidence
- D22 was effective against Pseudomonas aeruginosa, Escherichia coli, and Acinetobacter baumannii in murine models.
- Survival rates in zebrafish embryos infected with A. baumannii improved significantly with D22 treatment.
- D22 demonstrated a favorable safety profile in various cell lines.
- Pharmacokinetic studies showed D22 had good tissue distribution in mice.
Takeaway
Scientists tested a new antibiotic called D22 to see if it could help fight bad germs that make people sick, and it worked really well in mice.
Methodology
The study involved in vivo testing of D22 in murine models of infection, including thigh infection, peritonitis, and urinary tract infection.
Limitations
The study primarily focused on murine models, which may not fully replicate human responses.
Participant Demographics
Mice were used in the study, specifically C57BL/6 and CD-1 strains.
Statistical Information
P-Value
p < 0.0001
Statistical Significance
p < 0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website